Success of 14-day triple and quadruple therapy for the control of Helicobacter pylori infections in Kohat district
DOI:
https://doi.org/10.33393/dti.2022.2481Keywords:
Helicobacter pylori, Peptic ulcer, gastric mucosa, intestinal metaplasia,, gastric pathologyAbstract
Introduction: Helicobacter pylori is an important medical pathogen present in more than half of the world’s population. Various treatment regimen are in use for the eradication of H. pylori, but due to the emergence of antibiotic resistance, its management is a big issue for clinicians.
Methods: In this study all suspected cases that had visited District Headquarters Hospital Kohat were considered for screening of H. pylori infections. Preliminary information about their age, gender, general health conditions, occupation, etc. was taken for consideration. After recording initial signs and symptoms, samples were considered for H. pylori detection using stool antigen test and endoscopy. Fourteen-day proton pump inhibitor base triple and quadruple therapy were administered to each patient.
Results: In total (n = 178), there were high numbers of positivity in patients aged below 30 years (82; 46.06%), most of whom belonged to rural areas.
Conclusion: This study concludes that there were high numbers of positive patients aged below 30 years, and according to this study MEL (Metronidazole + Esomeprazole + Levofloxacin) is the most effective treatment regimen for the eradication of H. pylori.
Downloads
References
Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-429. https://doi.org/10.1053/j.gastro.2017.04.022 PMID:28456631 DOI: https://doi.org/10.1053/j.gastro.2017.04.022
Eshraghian A. Epidemiology of Helicobacter pylori infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: a systematic review of prevalence and risk factors. World J Gastroenterol. 2014;20(46):17618-17625. https://doi.org/10.3748/wjg.v20.i46.17618 PMID:25516677 DOI: https://doi.org/10.3748/wjg.v20.i46.17618
Qadri Q, Rasool R, Gulzar GM, Naqash S, Shah ZAH. H. pylori infection, inflammation and gastric cancer. J Gastrointest Cancer. 2014;45(2):126-132. https://doi.org/10.1007/s12029-014-9583-1 PMID:24557546 DOI: https://doi.org/10.1007/s12029-014-9583-1
Scott DR, Marcus EA, Wen Y, Oh J, Sachs G. Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. Proc Natl Acad Sci USA. 2007;104(17):7235-7240. https://doi.org/10.1073/pnas.0702300104 PMID:17438279 DOI: https://doi.org/10.1073/pnas.0702300104
Al-Khattaf AS. Helicobacter pylori virulence markers in gastroduodenal disorders. Detection of cytotoxin-associated gene A and vacuolating cytotoxin-associated gene A genes in Saudi patients. Saudi Med J. 2012;33(7):716-721. PMID:22821304
Ribeiro ML, Godoy APO, Benvengo YHB, Mendonça S, Pedrazzoli J Jr. Clinical relevance of the cagA, vacA and iceA genotypes of Helicobacter pylori in Brazilian clinical isolates. FEMS Immunol Med Microbiol. 2003;36(3):181-185. https://doi.org/10.1016/S0928-8244(03)00029-4 PMID:12738389 DOI: https://doi.org/10.1016/S0928-8244(03)00029-4
Abadi ATB. Strategies used by helicobacter pylori to establish persistent infection. World J Gastroenterol. 2017;23(16):2870-2882. https://doi.org/10.3748/wjg.v23.i16.2870 PMID:28522905 DOI: https://doi.org/10.3748/wjg.v23.i16.2870
Omosor KI, Omosor OH, Ibeh IN, et al. Seroprevalence of Helicobacter pyloriInfection and Risk Factors among Asymptomatic Subjects in Delta State, Nigeria. Adv Microbiol. 2017;7(9):641-652. https://doi.org/10.4236/aim.2017.79050 DOI: https://doi.org/10.4236/aim.2017.79050
Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868-876. https://doi.org/10.1111/apt.14561 PMID:29430669 DOI: https://doi.org/10.1111/apt.14561
Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283-297. https://doi.org/10.1093/oxfordjournals.epirev.a018040 PMID:11218379 DOI: https://doi.org/10.1093/oxfordjournals.epirev.a018040
Rothenbacher D, Bode G, Berg G, et al. Helicobacter pylori among preschool children and their parents: evidence of parent-child transmission. J Infect Dis. 1999;179(2):398-402. https://doi.org/10.1086/314595 PMID:9878024 DOI: https://doi.org/10.1086/314595
Nurgalieva ZZ, Malaty HM, Graham DY, et al. Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. Am J Trop Med Hyg. 2002;67(2):201-206. https://doi.org/10.4269/ajtmh.2002.67.201 PMID:12389948 DOI: https://doi.org/10.4269/ajtmh.2002.67.201
Xie Y, Zhu Y, Zhou, H, et al. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. World J Gastroenterol. 2014;20(32):11415-21. https://doi.org/10.3748/wjg.v20.i32.11415 PMID: 25170230 DOI: https://doi.org/10.3748/wjg.v20.i32.11415
Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41(8):768-775. https://doi.org/10.1111/apt.13128 PMID:25703120 DOI: https://doi.org/10.1111/apt.13128
Zhong Z, Zhang Z, Wang J, et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China. Am J Cancer Res. 2021;11(10):5027-5037. PMID:34765309
Saracino IM, Pavoni M, Zullo A, et al. Antibiotic resistance and therapy outcome in H. pylori eradication failure patients. Antibiotics (Basel). 2020;9(3):121. https://doi.org/10.3390/antibiotics9030121 PMID:32183165 DOI: https://doi.org/10.3390/antibiotics9030121
AlRuthia Y, Almadi MA, Alqahtani S, Alrasheed H, Al-Owairdhi M, Alsohaibani F. The cost-effectiveness of sequential versus standard triple therapy for Helicobacter pylorieradication in Saudi Arabia. Saudi J Gastroenterol. 2021 Jul-Aug;27(4):217-222. https://doi.org/10.4103/sjg.sjg_536_20 PMID:34259193 DOI: https://doi.org/10.4103/sjg.sjg_536_20
Hsu PI, Tsay FW, Kao JY, et al; Taiwan Acid-related Disease, Microbiota (TARD-M) Consortium. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter. 2021;26(5):e12840. https://doi.org/10.1111/hel.12840 PMID:34390083 DOI: https://doi.org/10.1111/hel.12840
Iranikhah A, Ghadir MR, Sarkeshikian S, Saneian H, Heiari A, Mahvari M. Stool antigen tests for the detection of Helicobacter pylori in children. Iran J Pediatr. 2013;23(2):138-142. PMID:23724172
Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233-238. https://doi.org/10.1111/j.1523-5378.2010.00758.x PMID:20557366 DOI: https://doi.org/10.1111/j.1523-5378.2010.00758.x
Wang XM, Yee KC, Hazeki-Taylor N, et al. Oral Helicobacter pylori, its relationship to successful eradication of gastric H. pylori and saliva culture confirmation. J Physiol Pharmacol. 2014;65(4):559-566. PMID:25179088
Fujimoto Y, Furusyo N, Toyoda K, Takeoka H, Sawayama Y, Hayashi J. Intrafamilial transmission of Helicobacter pylori among the population of endemic areas in Japan. Helicobacter. 2007;12(2):170-176. https://doi.org/10.1111/j.1523-5378.2007.00488.x PMID:17309755 DOI: https://doi.org/10.1111/j.1523-5378.2007.00488.x
Kouitcheu Mabeku LB, Bello Epesse M, Fotsing S, Kamgang R, Tchidjo M; KouitcheuMabeku. L. B., Bello Epesse, M., Fotsing, S., Kamgang, R., &Tchidjo, M. Stool antigen testing, a reliable noninvasive method of assessment of Helicobacter pylori infection among patients with gastro-duodenal disorders in Cameroon. Dig Dis Sci. 2021;66(2):511-520. https://doi.org/10.1007/s10620-020-06219-0 PMID:32350723 DOI: https://doi.org/10.1007/s10620-020-06219-0
Salem OE, Youssri AH, Mohammad ON. The prevalence of H. pylori antibodies in asymptomatic young egyptian persons. J Egypt Public Health Assoc. 1993;68(3-4):333-352. PMID:17265652
Contreras M, Fernández-Delgado M, Reyes N, García-Amado MA, Rojas H, Michelangeli F. Helicobacter pylori Infection in rural and urban dyspeptic patients from Venezuela. Am J Trop Med Hyg. 2015;93(4):730-732. https://doi.org/10.4269/ajtmh.15-0021 PMID:26195456 DOI: https://doi.org/10.4269/ajtmh.15-0021
Waldum HL, Kleveland PM, Sørdal ØF. Helicobacter pylori and gastric acid: an intimate and reciprocal relationship. Therap Adv Gastroenterol. 2016;9(6):836-844. https://doi.org/10.1177/1756283X16663395 PMID:27803738 DOI: https://doi.org/10.1177/1756283X16663395
Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20(1):99-107. https://doi.org/10.1111/j.1365-2036.2004.02029.x PMID:15225176 DOI: https://doi.org/10.1111/j.1365-2036.2004.02029.x
Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol. 2005;11(20):3091-3098. https://doi.org/10.3748/wjg.v11.i20.3091PMID:15918196 DOI: https://doi.org/10.3748/wjg.v11.i20.3091
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 The Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to Drug Target Insights agree to publish their articles under the Creative Common Attribution Non Commercial 4.0 (CC-BY-NC 4.0) license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.
Accepted 2022-11-30
Published 2022-12-19
